MedTrace Logo

Dasatinib Holiday for Improved Tolerability

NCT02890784 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 291

Last updated 2023-05-10

No results posted yet for this study

Summary

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

Conditions

  • Myeloid Leukemia, Chronic

Interventions

DRUG

dasatinib (SPRYCEL®)

Treatment optimization for patients with chronic myeloid leukemia (CML)

Sponsors & Collaborators

  • University of Jena

    lead OTHER

Principal Investigators

  • Andreas Hochhaus, Prof. · Jena University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02890784 on ClinicalTrials.gov